Cargando…
Ramatroban as a Novel Immunotherapy for COVID-19
SARS-CoV-2 virus suppresses host innate and adaptive immune responses, thereby allowing the virus to proliferate, and cause multiorgan failure, especially in the elderly. Respiratory viruses stimulate cyclooxygenase-2 (COX-2) to generate prostanoids including Prostaglandin D(2) (PGD(2)) and thrombox...
Autores principales: | Gupta, Ajay, Kalantar-Zadeh, Kamyar, Reddy, Srinivasa T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500620/ https://www.ncbi.nlm.nih.gov/pubmed/32952595 http://dx.doi.org/10.37421/jmgm.2020.14.457 |
Ejemplares similares
-
The effect of ramatroban on cytokine and thrombotic storms in Covid-19
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2022) -
Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor
por: Chakraborty, Raja, et al.
Publicado: (2014) -
Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A(2) and Prostaglandin D(2) Receptor Antagonist: A Four-Patient Case Series Report
por: Ogletree, Martin L., et al.
Publicado: (2022) -
Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2020) -
COVID‐19: a major cause of cachexia and sarcopenia?
por: Morley, John E., et al.
Publicado: (2020)